Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated ...

Related Keywords

Stanford ,California ,United States ,Stanford University ,Foster City ,Santa Monica ,Chris Mcdonald ,David Miklos ,Cindy Perettie ,Yescarta Axicabtagene Ciloleucel ,Gilead Company ,Gilead Sciences ,Gilead Company Nasdaq ,Exchange Commission ,Cell Therapy At Stanford University ,Drug Administration ,Gilead Sciences Inc ,Kite Authorized Treatment Centers ,New Median Turnaround Time ,Product Release ,Support Kite ,Industry Leading Overall Turnaround Time ,Critical Factor ,Therapy Patients ,Executive Vice President ,Chimeric Antigen Receptor ,Marrow Transplant ,Cell Therapy ,Global Head ,Technical Operations ,Axicabtagene Ciloleucel ,Prescribing Information ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Private Securities Litigation Reform Act ,Quarterly Report ,